Jefferies London Healthcare conference presentation 2025
Efficient In Vivo Generation of CAR T Cells using a Retargeted Fourth-Generation Lentiviral Vector
The TetraVecta™ System: Optimisation & Exemplification of OXB’s Next Generation Lentiviral Vector
What’s Upstream of Downstream Matters: Utilising High-Efficiency Secreted Nuclease (SecNuc™ Enzyme) and Transgene Repression (TRiP System™) to Improve rAAV Production
Development and Scale Up of Next Generation Lentiviral Vector Batch Process Demonstrating Increased Productivity and Enhanced Purity
Interim results for 6 months ended 30 June 2025
2 October 2025
Interim results for the six months ended 30 June 2025
23 September 2025
OXB Interim Results Presentation 2025
23 September 2025
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025
23 September 2025
Case Study: Tech transfer across borders: transferring lentivirus manufacture from the UK to France
September 2025
Increasing AAV Productivity Upstream Process Optimization for a Robust, Plug-and-Play Platform
